Scientists have identified a pair of neutralising antibodies
Scientists have identified a pair of neutralising antibodies - isolated from a patient who recovered from COVID-19 - that may offer therapeutic benefits, and help design molecule antivirals and vaccine candidates to fight the SARS-CoV-2 virus.
Scientists have identified a pair of neutralizing antibodies — isolated from a patient recovered from COVID-19 — that can provide therapeutic benefits and help develop antiviral molecules and vaccine candidates to combat SARS-CoV-2.
The antibodies identified by the researchers, including those from Chinese Academy of Sciences, bind to the glycoprotein spike of the SARS-COV-2 virus, blocking the spike's ability to bind to the human ACE2 receptor and mediate viral entry into host cells.
The antibodies found by the researchers, including those from the Chinese Academy of Sciences, bind to the SARS-COV-2 glycoprotein spike, blocking the ability of the spike to bind to the human ACE2 receptor and mediating viral entry into host cells.
Preliminary tests of the two antibodies, named B38 and H4, in a mouse model resulted in a reduction of virus titers, the researchers said. The finding, published in the journal Science, suggests that the
Preliminary testing of the two antibodies, called B38 and H4, resulted in virus titers decreasing in a mouse model , the researchers said. The result, published in Science, indicates the
antibodies may offer therapeutic benefits - In addition to informing the design of small molecule therapeutics and vaccine candidates to fight COVID-19, they said.
Antibodies that offer therapeutic benefits-they said, in addition to informing the design of small molecule therapy and vaccine candidates to counter COVID-19.
Researcher Yan Wu from Capital Medical University, China and colleagues found that the antibodies can each bind simultaneously to different epitopes on the spike's receptor binding domain (RBD).
Researcher Yan Wu from Capital Medical University, China and colleagues found that the antibodies on the spike's receptor binding domain (RBD) can each bind simultaneously to specific epitopes.
Due to this binding, both antibodies together may confer a stronger neutralising effect than either antibody on its own -- a prediction supported by In vitro experiments, they said.
Because of this binding, both antibodies together can have a stronger neutralizing effect than either of them on their own — a prediction supported by experiments with In vitro, they said.
This feature also means that should one of the viral epitopes mutate in a way that prevents the binding of one of the two antibodies, the other may still retain its neutralising activity, according to the researchers. By imaging the structureb of the viral spike's RBD bound to B38, the team confirmed that the antibody binds to a subset of the amino acids bound by ACE2, they said.
This feature also means that if one of the viral epitopes mutates in a way that prevents the binding of one of the two antibodies, according to the researchers, the other may still retain its neutralizing activity. By imaging the RBD structureb of the viral spike bound to B38, the team confirmed that the antibody binds to a subset of the ACE2-bound amino acids, they said.
This, the researchers explained, provides an explanation for why the B38 antibody confers such strong neutralising effects. They suggest that a "cocktail" containing both antibodies could provide direct therapeutic benefits for COVID-19 patients.
This offers an explanation for why the B38 antibody confers such strong neutralizing effects, the researchers explained. They propose that a "cocktail" containing both antibodies may offer direct therapeutic benefits to patients with COVID-19.
The finding regarding the viral spike epitopes could also aid the development of small molecule antivirals and vaccine candidates to fight the SARS-CoV-2 virus, the researchers added...
Researchers added that learning about the viral spike epitopes could also help improve small molecule antivirals and vaccine candidates to combat the SARS-CoV-2 virus.
Scientists have identified a pair of neutralizing antibodies — isolated from a patient recovered from COVID-19 — that can provide therapeutic benefits and help develop antiviral molecules and vaccine candidates to combat SARS-CoV-2.
The antibodies identified by the researchers, including those from Chinese Academy of Sciences, bind to the glycoprotein spike of the SARS-COV-2 virus, blocking the spike's ability to bind to the human ACE2 receptor and mediate viral entry into host cells.
The antibodies found by the researchers, including those from the Chinese Academy of Sciences, bind to the SARS-COV-2 glycoprotein spike, blocking the ability of the spike to bind to the human ACE2 receptor and mediating viral entry into host cells.
Preliminary tests of the two antibodies, named B38 and H4, in a mouse model resulted in a reduction of virus titers, the researchers said. The finding, published in the journal Science, suggests that the
Preliminary testing of the two antibodies, called B38 and H4, resulted in virus titers decreasing in a mouse model , the researchers said. The result, published in Science, indicates the
antibodies may offer therapeutic benefits - In addition to informing the design of small molecule therapeutics and vaccine candidates to fight COVID-19, they said.
Antibodies that offer therapeutic benefits-they said, in addition to informing the design of small molecule therapy and vaccine candidates to counter COVID-19.
Researcher Yan Wu from Capital Medical University, China and colleagues found that the antibodies can each bind simultaneously to different epitopes on the spike's receptor binding domain (RBD).
Researcher Yan Wu from Capital Medical University, China and colleagues found that the antibodies on the spike's receptor binding domain (RBD) can each bind simultaneously to specific epitopes.
Due to this binding, both antibodies together may confer a stronger neutralising effect than either antibody on its own -- a prediction supported by In vitro experiments, they said.
Because of this binding, both antibodies together can have a stronger neutralizing effect than either of them on their own — a prediction supported by experiments with In vitro, they said.
This feature also means that should one of the viral epitopes mutate in a way that prevents the binding of one of the two antibodies, the other may still retain its neutralising activity, according to the researchers. By imaging the structureb of the viral spike's RBD bound to B38, the team confirmed that the antibody binds to a subset of the amino acids bound by ACE2, they said.
This feature also means that if one of the viral epitopes mutates in a way that prevents the binding of one of the two antibodies, according to the researchers, the other may still retain its neutralizing activity. By imaging the RBD structureb of the viral spike bound to B38, the team confirmed that the antibody binds to a subset of the ACE2-bound amino acids, they said.
This, the researchers explained, provides an explanation for why the B38 antibody confers such strong neutralising effects. They suggest that a "cocktail" containing both antibodies could provide direct therapeutic benefits for COVID-19 patients.
This offers an explanation for why the B38 antibody confers such strong neutralizing effects, the researchers explained. They propose that a "cocktail" containing both antibodies may offer direct therapeutic benefits to patients with COVID-19.
The finding regarding the viral spike epitopes could also aid the development of small molecule antivirals and vaccine candidates to fight the SARS-CoV-2 virus, the researchers added...
Researchers added that learning about the viral spike epitopes could also help improve small molecule antivirals and vaccine candidates to combat the SARS-CoV-2 virus.
Comments
Post a Comment